Apollomics, Inc.
APLMHealthcare|Biotechnology|US
$19.00
+2.02 (+11.90%)
Cash / Share
$7.78
Analyst Consensus
Buy2 analysts
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
Rating Trend
Jun 24
1 buy · 0 hold · 0 sell
Jul 24
1 buy · 0 hold · 0 sell
Aug 24
1 buy · 0 hold · 0 sell
Sep 24
1 buy · 0 hold · 0 sell
Oct 24
1 buy · 0 hold · 0 sell
Nov 24
1 buy · 0 hold · 0 sell
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | May 8, 2024 |
| EF Hutton | maintain | Buy | Apr 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 20, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 3, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 5, 2023 |
Earnings History
Next report: Apr 1, 2027| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Apr 27, 2026 | $3.80 | — | — | — |
| Jul 3, 2025 | $-11.37 | — | $8.5M | — |
| Apr 3, 2025 | $-16.92 | — | -$1.6M | — |
| Aug 14, 2024 | $-37.56 | — | $1.8M | — |
| Mar 28, 2024 | $-24.00 | $-0.16 | $333.0K | — |
| Sep 28, 2023 | $-2.55 | $-0.00 | $488.0K | — |
| Apr 28, 2023 | $-0.00 | $-0.16 | -$272.0K | — |
News
Apollomics Announces $10 Million Private Placement Transaction
FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), f…
Aug 11, 2026globenewswire.com